Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping - PubMed (original) (raw)
Clinical Trial
Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping
Tory P Sullivan et al. Dermatol Surg. 2003 Dec.
Abstract
Objective: To characterize the immune response and the apoptotic pathways that result in regression of imiquimod-treated basal cell carcinomas (BCCs).
Methods: The trial was conducted as an open-label, matched controlled, nonrandomized study. Twelve patients were assigned as either active-treatment patients or matched control subjects. After treatment, lesions were excised and stained for CD20, CD3, CD4, CD56, bcl-2, bax, caspase-3, and p53. Additionally, a DNA fragmentation assay was performed using the terminal deoxynucleotidyltransferase-mediated dUTP nick-end-labeling method.
Results: All vehicle-treated BCCs (six of six) had residual tumor compared with four of six imiquimod-treated BCCs. A dense mononuclear infiltrate surrounded all of the imiquimod-treated tumors and only one of six vehicle-treated BCCs. Staining for CD20, CD3, and CD4 revealed that the infiltrate consisted primarily of T-helper lymphocytes; however, a significant portion of the cells stained positively for CD56, indicating the presence of natural killer cells. Imiquimod-treated BCCs stained more strongly for caspase-3 and to a lesser degree p53 as compared with vehicle-treated BCCs. No differences were seen in either bax or bcl-2 staining. Minimal apoptosis was seen with the terminal deoxynucleotidyltransferase-mediated dUTP nick-end-labeling assay in either group.
Conclusion: This study provides evidence that imiquimod's antitumorigenic effects are mediated via up regulation of local interferon-alpha levels and supports previous work, suggesting that increased natural killer cell activity may be an important factors explaining both spontaneous regression and IFN-alpha induced regression of BCC.
Similar articles
- Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D, Matías-Guiu X, Alomar A. Vidal D, et al. Clin Exp Dermatol. 2004 Sep;29(5):518-25. doi: 10.1111/j.1365-2230.2004.01601.x. Clin Exp Dermatol. 2004. PMID: 15347339 Clinical Trial. - In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma.
De Giorgi V, Salvini C, Chiarugi A, Paglierani M, Maio V, Nicoletti P, Santucci M, Carli P, Massi D. De Giorgi V, et al. Int J Dermatol. 2009 Mar;48(3):312-21. doi: 10.1111/j.1365-4632.2009.03916.x. Int J Dermatol. 2009. PMID: 19261026 Clinical Trial. - Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle.
Berman B, Sullivan T, De Araujo T, Nadji M. Berman B, et al. Br J Dermatol. 2003 Nov;149 Suppl 66:59-61. doi: 10.1046/j.0366-077x.2003.05634.x. Br J Dermatol. 2003. PMID: 14616354 Clinical Trial. - Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.
Drehs MM, Cook-Bolden F, Tanzi EL, Weinberg JM. Drehs MM, et al. Dermatol Surg. 2002 May;28(5):427-9. doi: 10.1046/j.1524-4725.2002.01231.x. Dermatol Surg. 2002. PMID: 12030878 Review. - Treatment of a large superficial basal cell carcinoma with 5% imiquimod: a case report and review of the literature.
Chen TM, Rosen T, Orengo I. Chen TM, et al. Dermatol Surg. 2002 Apr;28(4):344-6. doi: 10.1046/j.1524-4725.2002.01140.x. Dermatol Surg. 2002. PMID: 11966794 Review.
Cited by
- Natural Killer Cell Recognition and Control of Epithelial Cancers.
de Souza Fernandez Pereira M, Carr DR, Gatti-Mays ME, Olsen MR, Setty BA, Shahwan KT, Lee DA. de Souza Fernandez Pereira M, et al. Cancer J. 2022 Jul-Aug 01;28(4):263-269. doi: 10.1097/PPO.0000000000000610. Cancer J. 2022. PMID: 35880935 Free PMC article. - Treatment of locally advanced cutaneous Merkel cell carcinoma with topical imiquimod.
Saini K, Chee P. Saini K, et al. JAAD Case Rep. 2021 Apr 13;13:121-123. doi: 10.1016/j.jdcr.2021.04.003. eCollection 2021 Jul. JAAD Case Rep. 2021. PMID: 34195321 Free PMC article. No abstract available. - Current Insights in Cutaneous Lupus Erythematosus Immunopathogenesis.
Garelli CJ, Refat MA, Nanaware PP, Ramirez-Ortiz ZG, Rashighi M, Richmond JM. Garelli CJ, et al. Front Immunol. 2020 Jul 2;11:1353. doi: 10.3389/fimmu.2020.01353. eCollection 2020. Front Immunol. 2020. PMID: 32714331 Free PMC article. Review. - Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells.
Fishelevich R, Zhao Y, Tuchinda P, Liu H, Nakazono A, Tammaro A, Meng TC, Lee J, Gaspari AA. Fishelevich R, et al. J Immunol. 2011 Aug 15;187(4):1664-73. doi: 10.4049/jimmunol.1100755. Epub 2011 Jul 15. J Immunol. 2011. PMID: 21765012 Free PMC article. - Treatment of cutaneous tumors with topical 5% imiquimod cream.
Alessi SS, Sanches JA, Oliveira WR, Messina MC, Pimentel ER, Festa Neto C. Alessi SS, et al. Clinics (Sao Paulo). 2009;64(10):961-6. doi: 10.1590/S1807-59322009001000005. Clinics (Sao Paulo). 2009. PMID: 19841702 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous